Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16682364 | 0.80 | HASPIN (0.35) | MEN1KMT2A | |
| SCHEMBL12062616 | 0.79 | MEN1 (0.46) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL16683500 | 0.77 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL29699212 | 0.77 | HPGD (0.37) | MEN1KMT2AKDM4EALDH1A1PRNP | |
| SCHEMBL15263601 | 0.77 | HPGD (0.37) | MEN1KMT2AKDM4EALDH1A1PRNP | |
| SCHEMBL29427263 | 0.77 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL15263389 | 0.77 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL15280746 | 0.74 | ALDH1A1 (0.37) | KDM4EALDH1A1MAPTPRNPNPSR1 | |
| SCHEMBL21761868 | 0.72 | FGFR4 (0.36) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL31648322 | 0.71 | FGFR1 (0.45) | AURKAKDRAURKBDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334267-B2 | RAF inhibitor compounds | DECIPHERA PHARMACEUTICALS, LLC (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150119392-A1 | RAF INHIBITOR COMPOUNDS | DECIPHERA PHARMACEUTICALS, LLC | 2015-04-30 | — | — | US | disclosed |
| US-8741911-B2 | Raf inhibitor compounds | ELI LILLY AND COMPANY (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130252977-A1 | Raf Inhibitor Compounds | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252977-A1 | Raf Inhibitor Compounds | BRAF, RAF1, ARAF | MEN1 2606/4885KMT2A 1103/4885KDM4E 1467/4885 |
| US-20150119392-A1 | RAF INHIBITOR COMPOUNDS | BRAF, RAF1, NRAS | MEN1 426/4885KMT2A 1631/4885KDM4E 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.